Interaction between apolipoprotein E genotype and hypertension on cognitive function in older women in the Nurses’ Health Study


Autoři: Iris Y. Kim aff001;  Francine Grodstein aff001;  Peter Kraft aff001;  Gary C. Curhan aff001;  Katherine C. Hughes aff005;  Hongyan Huang aff001;  Jae H. Kang aff003;  David J. Hunter aff001
Působiště autorů: Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America aff001;  Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom aff002;  Department of Medicine, Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America aff003;  Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America aff004;  Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America aff005
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0224975

Souhrn

Objective

To examine the interaction between APOE genotypes and both treated and untreated hypertension on cognitive function in an updated analysis of Nurses’ Health Study (NHS) data.

Design

At baseline (1995–2001) and 3 biennial follow-up assessments over ~6 years, cognitive function was assessed.

Setting and participants

8300 NHS participants aged 70+ years underwent a cognitive battery, which comprised 6 tests including the Telephone Interview for Cognitive Status (TICS) and tests of verbal memory, category fluency, and working memory.

Measures

We estimated the mean differences in average cognitive scores across up to 4 assessments using multiple linear regression. We also tested for interaction between APOE e4 allele carrier status and hypertension overall, as well as for apparently untreated and treated hypertension.

Results

We confirmed that, compared with those with APOE e3/3 genotype, APOE e4 allele carriers scored lower by 0.55 units on the average TICS score (95%CI:-0.67,-0.43). We also observed a significantly worse average TICS score among women with untreated hypertension compared with women without hypertension (difference = -0.23, 95%CI:-0.37,-0.09), while no significant difference was observed for women with treated hypertension. Significant interaction was detected between the APOE e4 allele and untreated hypertension (p-int = 0.02 for the TICS; p-int = 0.045 for global score), but not with treated hypertension. Specifically, compared with normotensive women with the APOE e3/3 genotype, APOE e4 allele carriers with treated hypertension scored lower by 0.50 units (95%CI:-0.69,-0.31); however, the APOE e4 allele carriers with untreated hypertension scored lower by 1.02 units on the TICS score (95%CI:-1.29, -0.76). This interaction of APOE e4 and untreated hypertension was also consistently observed for the global score.

Conclusions

Women with hypertension and at least one APOE e4 allele had worse average cognitive function compared with women without hypertension with the e3/3 genotype; this difference was amplified among APOE e4 allele carriers with untreated hypertension.

Klíčová slova:

Cognitive impairment – Cognitive psychology – Heredity – Hypertension – Memory recall – Nurses – Variant genotypes – Working memory


Zdroje

1. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PS, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele ϵ4 with late-onset familial and sporadic Alzheimer’s disease. Neurology. 1993;43: 1467–1467. doi: 10.1212/wnl.43.8.1467 8350998

2. Corder E, Saunders A, Strittmatter W, Schmechel D, Gaskell P, Small G, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261: 921. doi: 10.1126/science.8346443 8346443

3. Caselli RJ, Reiman EM, Locke DE, Hutton ML, Hentz JG, Hoffman-Snyder C, et al. Cognitive domain decline in healthy apolipoprotein E ε4 homozygotes before the diagnosis of mild cognitive impairment. Archives of neurology. 2007;64: 1306–1311. doi: 10.1001/archneur.64.9.1306 17846270

4. Farrer LA, Cupples L, Haines JL, Hyman B, Kukkull WA, Mayeux R. Effects of age, sex, and ethnicity on the association between apolipoprotein e genotype and alzheimer disease: A meta-analysis. JAMA. 1997;278: 1349–1356.

5. Lahoz C, Schaefer EJ, Cupples LA, Wilson PWF, Levy D, Osgood D, et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis. 2001;154: 529–537. doi: 10.1016/s0021-9150(00)00570-0 11257253

6. Goldman JS, Hahn SE, Catania JW, LaRusse-Eckert S, Butson MB, Rumbaugh M, et al. Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genetics in Medicine. 2011;13: 597–605. doi: 10.1097/GIM.0b013e31821d69b8 21577118

7. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function: The honolulu-asia aging study. JAMA. 1995;274: 1846–1851. doi: 10.1001/jama.1995.03530230032026 7500533

8. Skoog I, Nilsson L, Persson G, Lernfelt B, Landahl S, Palmertz B, et al. 15-year longitudinal study of blood pressure and dementia. The Lancet. 1996;347: 1141–1145.

9. Yasuno F, Tanimukai S, Sasaki M, Ikejima C, Yamashita F, Kodama C, et al. Effect of plasma lipids, hypertension and APOE genotype on cognitive decline. Neurobiology of Aging. 2012;33: 2633–2640. doi: 10.1016/j.neurobiolaging.2011.12.028 22285757

10. Bangen KJ, Beiser A, Delano-Wood L, Nation DA, Lamar M, Libon DJ, et al. APOE Genotype Modifies the Relationship between Midlife Vascular Risk Factors and Later Cognitive Decline. Journal of Stroke and Cerebrovascular Diseases. 2013;22: 1361–1369. doi: 10.1016/j.jstrokecerebrovasdis.2013.03.013 23601373

11. Kang JH, Logroscino G, De Vivo I, Hunter D, Grodstein F. Apolipoprotein E, cardiovascular disease and cognitive function in aging women. Neurobiology of Aging. 2005;26: 475–484. doi: 10.1016/j.neurobiolaging.2004.05.003 15653176

12. Qiu C, Winblad B, Fastbom J, Fratiglioni L. Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD. Neurology. 2003;61: 655. doi: 10.1212/wnl.61.5.655 12963757

13. Carmelli D, Swan GE, Reed T, Miller B, Wolf PA, Jarvik GP, et al. Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins. Neurology. 1998;50: 1580. doi: 10.1212/wnl.50.6.1580 9633697

14. Peila R, White LR, Petrovich H, Masaki K, Ross GW, Havlik RJ, et al. Joint Effect of the APOE Gene and Midlife Systolic Blood Pressure on Late-Life Cognitive Impairment. Stroke. 2001;32: 2882. doi: 10.1161/hs1201.100392 11739991

15. Wang R, Fratiglioni L, Laukka EJ, Lövdén M, Kalpouzos G, Keller L, et al. Effects of vascular risk factors and APOE ε4 on white matter integrity and cognitive decline. Neurology. 2015;84: 1128–1135. doi: 10.1212/WNL.0000000000001379 25672924

16. Andrews S, Das D, Anstey KJ, Easteal S. Interactive effect of APOE genotype and blood pressure on cognitive decline: the PATH through life study. Journal of Alzheimer’s Disease. 2015;44: 1087–1098. doi: 10.3233/JAD-140630 25672766

17. de Frias CM, Schaie KW, Willis SL. Hypertension moderates the effect of APOE on 21-year cognitive trajectories. Psychology and Aging. 2014;29: 431–439. doi: 10.1037/a0036828 24956008

18. Nation D, Preis S, Beiser A, Bangen K, Delano-Wood L, Lamar M, et al. Pulse pressure is associated with early brain atrophy and cognitive decline: modifying effects of APOE4. Alzheimer disease and associated disorders. 2016;30: 210–215. doi: 10.1097/WAD.0000000000000127 27556935

19. Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB, et al. Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension. 2016;68: e67. doi: 10.1161/HYP.0000000000000053 27977393

20. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Genetic determinants of hair color and Parkinson’s disease risk. Annals of neurology. 2009;65: 76–82. doi: 10.1002/ana.21535 19194882

21. Lindström S, Loomis S, Turman C, Huang H, Huang J, Aschard H, et al. A comprehensive survey of genetic variation in 20,691 subjects from four large cohorts. PLOS ONE. 2017;12: e0173997. doi: 10.1371/journal.pone.0173997 28301549

22. Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson L, Rosner B, et al. Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. American Journal of Epidemiology. 1986;123: 894–900. doi: 10.1093/oxfordjournals.aje.a114319 3962971

23. Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB, Willett WC. Validity of Self-Reported Waist and Hip Circumferences in Men and Women. Epidemiology. 1990;1: 466–473. doi: 10.1097/00001648-199011000-00009 2090285

24. Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Hennekens CH, et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. The Lancet. 1991;338: 774–778. doi: 10.1016/0140-6736(91)90664-B

25. Kang JH, Grodstein F. Regular use of nonsteroidal anti-inflammatory drugs and cognitive function in aging women. Neurology. 2003;60: 1591. doi: 10.1212/01.wnl.0000065980.33594.b7 12771247

26. Brandt J, Spencer M, Folstein M. The telephone interview for cognitive status. JournalNeuropsychiatry, Neuropsychology and Behavioral Neurology. 1988;1: 111–117.

27. Korrick SA, Hunter DJ, Rotnitzky A, Hu H, Speizer FE. Lead and hypertension in a sample of middle-aged women. American Journal of Public Health. 1999;89: 330–335. doi: 10.2105/ajph.89.3.330 10076481

28. Flebach NH, Hebert PR, Stampfer MJ, Colditz GA, Willett WC, Rosner B, et al. A prospective study of high blood pressure and cardiovascular disease in women. American Journal of Epidemiology. 1989;130: 646–654. doi: 10.1093/oxfordjournals.aje.a115386 2773913

29. Tzourio C, Dufouil C, Ducimetière P, Alpérovitch A. Cognitive decline in individuals with high blood pressure. Neurology. 1999;53: 1948. doi: 10.1212/wnl.53.9.1948 10599763

30. Tadic M, Cuspidi C, Hering D. Hypertension and cognitive dysfunction in elderly: blood pressure management for this global burden. BMC Cardiovascular Disorders. 2016;16: 208. doi: 10.1186/s12872-016-0386-0 27809779

31. Hughes TM, Sink KM. Hypertension and Its Role in Cognitive Function: Current Evidence and Challenges for the Future. American Journal of Hypertension. 2016;29: 149–157. doi: 10.1093/ajh/hpv180 26563965

32. McDonald C, Pearce MS, Kerr SRJ, Newton JL. Blood pressure variability and cognitive decline in older people: a 5-year longitudinal study. Journal of Hypertension. 2017;35. Available: https://journals.lww.com/jhypertension/Fulltext/2017/01000/Blood_pressure_variability_and_cognitive_decline.22.aspx

33. Aronow WS. Hypertension and cognitive impairment. Annals of Translational Medicine. 2017;5: 259. doi: 10.21037/atm.2017.03.99 28706927

34. Kivipelto M, Helkala E-L, Hänninen T, Laakso MP, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and late-life mild cognitive impairment. Neurology. 2001;56: 1683. doi: 10.1212/wnl.56.12.1683 11425934

35. Haring B, Wu C, Coker LH, Seth A, Snetselaar L, Manson JE, et al. Hypertension, Dietary Sodium, and Cognitive Decline: Results From the Women’s Health Initiative Memory Study. American Journal of Hypertension. 2016;29: 202–216. doi: 10.1093/ajh/hpv081 26137952

36. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA. 2019;321: 553–561. doi: 10.1001/jama.2018.21442 30688979

37. Skoog I. A Review on Blood Pressure and Ischaemic White Matter Lesions. Dementia and Geriatric Cognitive Disorders. 1998;9(suppl 1): 13–19.

38. Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L. The role of apoe ∊4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA. 1999;282: 40–46. doi: 10.1001/jama.282.1.40 10404910

39. Kalmijn S, Feskens EJM, Launer LJ, Kromhout D. Cerebrovascular Disease, the Apolipoprotein e4 Allele, and Cognitive Decline in a Community-Based Study of Elderly Men. Stroke. 1996;27: 2230. doi: 10.1161/01.str.27.12.2230 8969786

40. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. The Lancet. 1997;349: 151–154. doi: 10.1016/S0140-6736(96)09328-2

41. Kester M, van der Flier W, Mandic G, Blankenstein M, Scheltens P, Muller M. Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer’s disease. J Alzheimers Dis. 2010;20: 1083–90. doi: 10.3233/JAD-2010-091198 20413898

42. Rodrigue KM, Rieck JR, Kennedy KM, Devous MD, Diaz-Arrastia R, Park DC. Risk Factors for β-Amyloid Deposition in Healthy Aging: Vascular and Genetic Effects. JAMA neurology. 2013;70: 600–606. doi: 10.1001/jamaneurol.2013.1342 23553344


Článek vyšel v časopise

PLOS One


2019 Číslo 11